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Abstract
Renal cell carcinoma (RCC) is the commonest from of renal neoplasm. Although surgery is a 
successful curative treatment for localized RCC, most patients are diagnosed with advanced 
or metastatic RCC, which has poor prognosis. RCC is classified by stage and grade using 
tissue samples. Whilst these provide good prognostic information, they are not very useful for 
early detection. Proteins that are dysregulated in patient’s serum can be a valuable alternative 
and less invasive biomarker for early detection of the disease. For this reason, a hypothesis 
was formed that leptin is a possible biomarker for early detection and prognostication of 
RCC. The literature has disparate results on the usefulness of leptin as a biomarker for the 
early detection of RCC. Hence, a systematic review and a meta-analysis was carried out to 
investigate whether serum leptin could be a reliable diagnostic and prognostic factor in RCC 
patients. Literature on the available cohort and case-control studies on serum leptin in RCC 
was searched in electronic databases and included to evaluate this adipokine in the 
progression of RCC. The relevant studies were evaluated for the diagnostic and prognostic 
value of leptin in RCC patients. Overall, only 6 original research studies matched selection 
criteria and were included for meta-analysis. This study was hypothesised that; leptin might 
be a useful biomarker for early detection and prognostication of RCC. However, the data 
were presented in this study did not support our hypothesis. Serum leptin levels in RCC 
patients do not strongly associate with the development or progression of RCC, thus cannot 
act as a biomarker for early detection in RCC in patients. Extending our hypothesis further to 
include levels of obesity and RCC development may be worthwhile, but studies are currently 
limited.
Keywords: Body mass index; Diagnostic factor; Kidney cancer; Obesity; Prognostic factor
  
1.0 BACKGROUND
Renal cell carcinoma (RCC) is the most lethal of all the common urologic cancers [1]. 
Numerous factors are thought to contribute to the growth and development of RCC such as 
cigarette smoking, consumption of alcohol, obesity, hypertension, reproductive and hormonal 
factors, lack of physical activity, diet, occupation, the environment, as well as genetics and 
pre-existing comorbidities [2]. There is a growing concern for the role of obesity in cancer 
development, with several studies finding that obesity increases the risk of malignancies, 
including RCC [3, 4].
Leptin (often abbreviated as Ob) is a 16kDa polypeptide. It is one of the adipokines 
that is secreted by adipocytes and is found at increased levels in the serum of obese people [5, 
6]. The hormone leptin was initially discovered in 1994 through its association with the 
homeostatic regulation of body weight [7]. The primary function of leptin is to maintain the 
food intake and energy expenditure in the human body, thus leptin is thought of as a satiety 
hormone. The high levels of circulating leptin in obese people reflect higher amounts of 
adipose tissue in the body, with a deficiency in, or resistance to, leptin perhaps contributing to 
severe obesity [8]. Studies have shown that leptin also activates other molecular pathways 
such as Janus kinase2-signal transducer and activator of transcription 3 (JAK2-STAT3), 
phosphoinositol-3 kinase (PI3K) and extracellular signal regulating kinase (ERK)1/2 which 
may promote cancer cell survival, proliferation and migration [9-11].
In the past years, the relationship between obesity and RCC has been studied, in 
particular to correlate any mechanism that underlies a relationship between leptin and RCC 
development and progression. To date, most studies have not identified the mechanism by 
which leptin may contribute to the development of RCC [12, 13]. Moreover, some studies 
have found that leptin levels are inversely proportional to development and progression of 
RCC, [14] whereas other studies report a positive association linking leptin and the 
  
development and progression RCC [15]. A hypothesis was formed based on the previous 
literature. In this paper, we hypothesised that leptin may be responsible for the progression of 
RCC and can be an early diagnostic and prognostic marker for RCC. Therefore, to support 
the mentioned hypothesis, a systematic review and a meta-analysis were carried out to 
analyze any association between leptin and the development and prognosis of RCC.
2.0 EVALUATING THE HYPOTHESIS BY USING SYSTEMATIC REVIEW AND 
META-ANALYSIS
The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 
flow diagram was used for selection of studies [16]. The Population, Intervention, 
Comparison and Outcome (PICO) method was used before initiating an electronic search 
[17]. 
2.1 Search strategy and study selection
Electronic databases used to identify relevant studies were PubMed, CINAHL, Web of 
Science, Science Direct and Google Scholar from the year 2000-2017. A comprehensive 
search strategy was developed using the following keywords: “leptin”, “Ob”, “adipokines” 
“adipose tissue”, “obesity”, “kidney cancer” and “renal cell carcinoma”. 
Three authors (KP, HWK and YNY) autonomously retrieved and assessed potentially 
applicable articles according to the specified selection criteria. Each study was required to 
meet the following criteria: (a) published as an original article from 2000 - 2017; (b) having 
definite description of leptin in RCC patients; (c) having description of cohort design; (d) 
serum leptin concentrations had to be provided; (e) and having investigator provided data on 
the number of cases with controls, with 95% confidence intervals (95% CIs) for 
quantification of leptin in RCC. The studies were excluded if they were case reports, meeting 
  
records, letters, review articles, or animal studies. Figure 1 demonstrates study selection by 
The PRISMA system that was used for this study.
The studies included in this meta-analysis were cohort studies. The quality of each 
included cohort study was evaluated by using the Newcastle-Ottawa Scale (NOS) by three 
independent authors [18]. The studies with 6 scores or more were classified as high quality 
studies. Table 2 shows Risk of Bias assessment for case control studies. Table 3 shows Risk 
of Bias assessment for cohort studies.
2.2 Data extraction for hypothesis evaluation
Reviewers (KP, HWK and YNY) extracted the data independently using a 
standardised data collection method. Extracted information included first author name, title of 
article, published year, country, number of patients, age range, stage and grade of tumour and 
subgroups of RCC with 95% CIs. Table 1 describes the characteristics of the selected studies 
(N = 6). Subgroups of RCC were defined as clear cell RCC (ccRCC) or non-ccRCC.
2.3 Statistical analysis of hypothesis
Prior to the statistical analysis, the results of included studies that are presented with 
median and inter-quarter range were changed to mean and standard deviation by the formula 
mentioned by Wan et al[18]. For prognostic value, stage and grade of RCC from I to IV were 
grouped as early (stage I & II) (grade I & II) and late (stage III & IV) (grade III & IV). The 
grouping was made by using the method as described in the Cochrane Handbook for 
Systematic Review of Interventions [19].
Review Manager Software version 5.3 was used to pool all the data of different 
outcomes in a meta-analysis. Diagnostic and prognostic value of leptin and concentration of 
leptin were pooled as mean difference. Statistical significance was determined at p<0.05 for 
  
all outcomes. The random effect model was used to pool the results if there was high clinical 
heterogeneity.
3.0 EMPIRICAL DATA OF HYPOTHESIS
3.1 Description of studies
Characteristics of the included studies are described in Table 1. Four out of six 
included studies analysing the diagnostic value of serum leptin in RCC patients. A total of 
1090 RCC patients versus 1056 controls were analysed [14, 15, 20, 21]. Three studies were 
evaluated for the prognostic value of serum leptin in RCC by early and late tumour stage. 190 
early stage cases versus 193 late stage cases were analysed [14, 22, 23]. Four studies were 
evaluated for the prognostic value of serum leptin in RCC by early and late grade. 226 early 
grade RCC versus 300 late grade RCC were analysed [14, 21-23]. Three studies were 
included for the evaluation of serum leptin in ccRCC compared with non-ccRCC. A total of 
247 ccRCC versus 78 non-ccRCC was analysed [14, 21, 22].
3.2 Evaluation of publication on leptin
Six included studies evaluated serum leptin solely or compared with other 
adipokines such as adiponectin, leptin receptor, insulin like growth factor 1 (IGF-1), retinoal-
binding protein 4 (RBP4), and nicotinamide phosphoribosyltranferase (NAMPT) which are 
secreted from adipoctytes. In the works by Choi et al., Liao et al. and Wang et al., leptin was 
compared with adiponectin, to identify the link between obesity and RCC [15, 20, 21, 24]. In 
all those studies, serum leptin levels were found to be inversely associated with prognosis of 
RCC [15, 20, 21, 24]. A study carried out by Rasmuson et al. found that IGF-1 rather than 
leptin was not associated with prognosis of RCC [23]. Horiguchi et al. found serum leptin to 
be a good indicator of RCC prognostication [22]. Figure 2 demonstrates the diagnostic value 
of serum leptin for RCC. Figure 3 demonstrates prognostic value of leptin by stage of RCC. 
  
Figure 4 demonstrates prognostic value of leptin by grade of RCC. Figure 5 demonstrates 
evaluation on leptin in ccRCC with non-ccRCC.
3.3 Association of leptin with RCC
The six studies of this meta-analysis (Table 1) were grouped into three specific 
objectives, with meta-analysis completed with RevMan version 5.3 for each specific 
objective. Forest plots were obtained.
3.3.1 Diagnostic value of leptin in RCC
The mean difference of leptin in RCC and control were analysed. Figure 2 shows 
serum leptin level was not associated with RCC, (mean difference= 1.39, 95% CI = -3.32 – 
6.10, P=0.56). 
3.3.2 Prognostic value of leptin in RCC
The mean differences of leptin in early and late stages of RCC were analysed. Figure 
3 shows no association when the concentration of leptin was compared in early stage (Stage I 
and II), with late stage (Stage III and IV) (mean difference= 0.82, 95% CI = -1.68 – 3.32, P = 
0.52). Hence, leptin level does not give any prognostic value in comparing early and late 
stage of RCC. When we stratified the studies based on grade of RCC (early and late), no 
association was found between the two groups. The mean difference was 0.07 (95% CI = -
0.56 – 0.70, p = 0.82). This is demonstrated in Figure 4.
  
3.3.3 Evaluation of leptin in ccRCC compared with non-ccRCC
The mean differences of leptin in ccRCC and non-ccRCC were analysed. Figure 5 
shows a significant difference on leptin level when ccRCC was compared with non-ccRCC. 
(mean difference = -6.41, 95% CI = -11.14 to -1.68, P=0.008).
4.0 THEORETICAL IMPLICATION
Leptin is an adipose-derived hormone that is manufactured in proportion to fat stores. 
Circulating leptin serves to relate the condition of body energy repletion to the central 
nervous system in order to suppress food intake and energy expenditure [25]. While leptin 
homeostasis takes place, it activates other molecular pathways, namely JAK2-STAT3, PI3K 
and ERK1/2 which promote cancer cell survival, proliferation and migration [26-28].
Multiples approaches were carried out for targeting leptin as a biomarker or factor in 
development and progression of RCC. However, there remain unanswered questions about 
the role or pathway of leptin in progression of the disease. This current meta-analysis 
included six different studies and demonstrated that the expression of leptin does not play a 
role in prognosis of RCC. This result appeared independent of the case control cohort, 
tumour-node-metastasis (TNM) staging, Fuhrman grading and subgroup of tumour RCC with 
leptin localization.
The meta-analysis of the diagnostic value of leptin shows leptin was not associated 
with the development and prognosis of RCC. Prognostic value analysis also shows leptin not 
significant in both early stages and grades compared to late stages and grades. In subgroup of 
RCC analysis, serum leptin was detected as significant in non-ccRCC cases. This suggests 
that leptin might play a role in non-ccRCC compared to ccRCC. 
  
Various objectives were formulated to evaluate the role of serum leptin in prognosis 
of RCC. However, none of the objectives correlated serum leptin with development and 
prognosis of RCC. Therefore, our meta-analysis with six studies indicates that leptin could 
not be a key biomarker for the early detection of RCC.
Some limitations exist in this meta-analysis. First, a small number of studies was 
included (six studies only) for analysis of leptin. Specifically, fewer than four studies were 
analysed for each objective. This could lead to publication bias. Second, significant 
heterogeneity was found in each analysis. This might be due to the sample collection, and the 
method used for analysis. Heterogeneity across studies cannot be completely discounted 
despite the use of appropriate meta-analytic techniques with random effect models. In 
conclusion, our hypothesis that serum leptin is a useful biomarker for early detection and 
prognostication of RCC was not supported by results of this systematic review and meta-
analysis. Since obesity is a known factor for RCC development and progression, future 
research should be carried out on a larger cohort or should study other adipokines that are 
secreted by adipocytes which might be biomarkers for the early detection of RCC.
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FIGURE LEGENDS
Figure 1
Study selection by The PRISMA system
This demonstrates the study selection by the PRISMA system that was used for the current 
systematic review and meta-analysis
Figure 2
Diagnostic value of leptin in RCC
Analysis shows diagnostic value of leptin in RCC compared to control
Figure 3
Prognostic value of leptin by stage in RCC
Analysis shows prognostic value of leptin in early stage compared to late stage of RCC
Figure 4
Prognostic value of leptin by grade in RCC
Analysis shows prognostic value of leptin in low grade compared to high grade of RCC
Figure 5
Evaluation of leptin in ccRCC with non-ccRCC
Analysis shows evaluation of leptin in ccRCC compared with non-ccRCC
  
Table 1 Characteristics of studies
Author Title Publication 
year
Country No of 
Participant
Age 
range
Mean SD Value
Diagnostic 
Value
Prognostic 
Value
Subgroup
Choi et al., Identifying the 
emerging role of 
adipokine as a 
diagnostic and 
prognostic biomarker 
of renal cell carcinoma
2016 Korea 54 RCC
25 control
49-66 Case 
2.93±0.63 (54)
Control 
2.85±0.32 (25)
NIL NIL
Horiguchi et 
al.,
Increased serum leptin 
levels and over 
expression of leptin 
receptors are 
associated with the 
invasion and 
progression of renal 
cell carcinoma
2006 New 
York
57 RCC 36-78 Early stage 
4.49±0.58 (36)
Late stage 
4.63±0.76  (21)
Early grade 
4.49±0.48 (51)
Late grade  
5.02±1.64  (6)  
ccRCC     
4.20±0.47
(39)
non-ccRCC
5.32±1.02 (18)
Liao et al., Serum leptin and 
adiponectin levels and 
risk of renal cell 
carcinoma
2013 USA Caucasians 
(RCC 581, 
control 558)
African American 
(RCC 187, 
control 359)
20-79 Case
29.76±6.49   
(768)
Control
21.26±4.23   
(917)
NIL NIL
Rasmuso et serum insulin-like 
growth factor-1 is an 
2009 Sweden 256 RCC 25-86 NIL Early stage 
71.56±12.44(10
NIL
  
al., independent predictor 
of prognosis in patients 
with renal cell 
carcinoma
7)
Late stage 
140.51±52.0(14
9)
Early grade 
163.04±12.1(55)
Late grade  
93.16±58.17 
(192)
Spyridopoul
os et al.,
Inverse association of 
leptin levels with renal 
cell carcinoma: Results 
from a case-control 
study
2009 Greece 70 RCC
28 control
22-83 Case
4.66±1.89    
(198)
Control
6.13±2.60     
(86)
Early stage 
31.25±7.34 (47)
Late stage 
16.14±6.22 (23)
Early stage 
72.37±11.03 
(31)
Late stage 
23.83±15.73 
(35)
ccRCC
8.43±8.06 (52)
non-ccRCC
29.99±4.08 (18)
Wang et al., Serum adiponectin 
level may be an 
independent predictor 
of clear cell renal cell 
carcinoma
2016 China 198 ccRCC
86 control
>18 Case
4.66±1.89    
(198)
Control
6.13±2.60     
(86)
Early grade 
4.52±2.19 (89)
Late grade  
4.14±2.48
(67)
ccRCC          
4.36±2.32 (156)
non-ccRCC  
4.39±2.31 (42)
RCC = renal cell carcinoma; ccRCC = clear cell renal cell carcinoma
  
Table 2 Risk of bias assessment for case control studies
Table 3 Risk of bias assessment for cohort studies
Included 
Studies
Year Selection Comparabi
lity
Exposure Total  
no of 
stars
Is case 
definition 
adequate
Representativeness 
of the cases
Selection 
of 
controls
Definition 
of control
Comparability of cases 
and control on the basis of 
the design or analysis
Ascertainment 
of exposure
Same method 
of 
ascertainment 
for cases & 
controls
Non- Response 
rate
Spyridopou
los et al
2009       - - 6
Liao et al 2013       - - 6
Wang et al 2016       - - 6
Choi et al 2016       - - 6
Included 
Studies
Year Selection Comparabi
lity
Outcome Total no of 
star
Representativeness 
of the exposed 
cohort
Selection 
of the 
non 
exposed 
cohort
Ascertainment 
of exposure
Demonstration 
that outcome of 
interest was not 
present at start 
of study
Comparability of 
cohorts on the 
basis of the 
design or analysis
Assessment 
of outcome
Was 
follow-up 
long 
enough for 
outcomes to 
occur
Adequacy of follow 
up of cohorts
Horiguchi 
et al
2006         8
R smuso 
et al
2009        8
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